InnovaRx Innova Health Strategies

D47.02

Systemic mastocytosis

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 6 never code together
D47.0code
Excludes1
  • congenital cutaneous mastocytosis (Q82.2)Q82.2
  • histiocytic neoplasms of uncertain behavior (D47.Z9)D47.Z9
  • malignant mast cell neoplasm (C96.2-)C96.2-
D47.02code
Excludes1
  • aggressive systemic mastocytosis (C96.21)C96.21
  • mast cell leukemia (C94.3-)C94.3-
D37-D48block
Excludes1
  • neoplasms of unspecified behavior (D49.-)D49.-

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 23
D47.02code
Inclusion terms
  • Indolent systemic mastocytosis
  • Isolated bone marrow mastocytosis
  • Smoldering systemic mastocytosis
  • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
Code also
  • , if applicable, any associated hematological non-mast cell lineage disease, such as:
  • acute myeloid leukemia (C92.6-, C92.A-)C92.6-C92.A-
  • chronic myelomonocytic leukemia (C93.1-)C93.1-
  • essential thrombocytosis (D47.3)D47.3
  • hypereosinophilic syndrome (D72.1)D72.1
  • myelodysplastic syndrome (D46.9)D46.9
  • myeloproliferative syndrome (D47.1)D47.1
  • non-Hodgkin lymphoma (C82-C85)C82-C85
  • plasma cell myeloma (C90.0-)C90.0-
  • polycythemia vera (D45)D45
D37-D48block
Notes
  • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.D37-D44D48
C00-D49chapter
Notes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).C25.9
Index entries leading here 3
  • Disease, diseased — see also Syndrome
    • systemic tissue mast cell D47.02
  • Mast cell
    • disease, systemic tissue D47.02
  • Mastocytosis D47.09
    • indolent systemic D47.02
    • isolated bone marrow D47.02
    • systemic (indolent) (smoldering)
      • with an associated hematological non-mast cell lineage disease (SM-AHNMD) D47.02
Alongside this code 2 same parent — D47.0
Medications 1

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

RX08HCC21

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
D47.0
Block
D37-D48
Siblings
2

Present FY2024–FY2027.